3 results
Approved WMOCompleted
To evaluate the safety and efficacy of abicipar (2 mg), compared to 0.5 mg ranibizumab in treatment-naïve patients with neovascular AMD.
Approved WMOCompleted
Primairy objective: Does the use of daily magnesium oxide reduce the prostate movements during a radiotherapy fraction? Secondary objectives: Does the use of magnesium oxide change the acute toxicity of the treatment? Does the use of magnesium oxide…
Approved WMOCompleted
· To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.